Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2015 2
2016 5
2018 1
2020 2
2021 1
2022 2
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Results by year

Filters applied: . Clear all
Page 1
Expert consensus on microtransplant for acute myeloid leukemia in elderly patients -report from the international microtransplant interest group.
Ai H, Chao NJ, Rizzieri DA, Huang X, Spitzer TR, Wang J, Guo M, Keating A, Krakow EF, Blaise D, Ma J, Wu D, Reagan J, Gergis U, Duarte RF, Chaudhary PM, Hu K, Yu C, Sun Q, Fuchs E, Cai B, Huang Y, Qiao J, Gottlieb D, Schultz KR, Liu M, Chen X, Chen W, Wang J, Zhang X, Li J, Huang H, Sun Z, Li F, Yang L, Zhang L, Li L, Liu K, Jin J, Liu Q, Liu D, Gao C, Fan C, Wei L, Zhang X, Hu L, Zhang W, Tian Y, Han W, Zhu J, Xiao Z, Zhou D, Zhang B, Jia Y, Zhang Y, Wu X, Shen X, Lu X, Zhan X, Sun X, Xiao Y, Wang J, Shi X, Zheng B, Chen J, Ding B, Wang Z, Zhou F, Zhang M, Zhang Y, Sun J, Xia B, Chen B, Ma L. Ai H, et al. Among authors: zhan x. Heliyon. 2023 Mar 31;9(4):e14924. doi: 10.1016/j.heliyon.2023.e14924. eCollection 2023 Apr. Heliyon. 2023. PMID: 37089296 Free PMC article. Review.
Recombinant human thrombopoietin (rhTPO) of different dosing regimens for refractory/relapsed primary immune thrombocytopenia: a multicenter, randomized controlled trial and pharmacokinetics study.
Liu X, Bai Y, Wang T, Song Y, Sun F, Xia R, Zhu F, Ma J, Lu Q, Ye X, Zhan X, Li L, Guo X, Cheng S, Li Y, Guo Z, Chen Y, Qian S, Qin L, Zhang Q, Cao S, Yang R. Liu X, et al. Among authors: zhan x. Platelets. 2023 Dec;34(1):2157806. doi: 10.1080/09537104.2022.2157806. Platelets. 2023. PMID: 36597010 Free article. Clinical Trial.
Low-dose PTCy plus low-dose ATG as GVHD prophylaxis after UD-PBSCT for hematologic malignancies: a prospective, multicenter, randomized controlled trial.
Zu Y, Gui R, Li Z, Wang J, Zhang Y, Yu F, Zhao H, Zhan X, Wang Z, Xing P, Wang X, Wang H, Song Y, Zhou J. Zu Y, et al. Among authors: zhan x. Blood Cancer J. 2023 Jan 11;13(1):10. doi: 10.1038/s41408-022-00771-w. Blood Cancer J. 2023. PMID: 36631450 Free PMC article. Clinical Trial. No abstract available.
Low-dose post-transplant cyclophosphamide with low-dose antithymocyte globulin for prevention of graft-versus-host disease in first complete remission undergoing 10/10 HLA-matched unrelated donor peripheral blood stem cell transplants: a multicentre, randomized controlled trial.
Zu Y, Li Z, Gui R, Liu Y, Zhang Y, Yu F, Zhao H, Fu Y, Zhan X, Wang Z, Xing P, Wang X, Wang H, Zhou J, Song Y. Zu Y, et al. Among authors: zhan x. Bone Marrow Transplant. 2022 Oct;57(10):1573-1580. doi: 10.1038/s41409-022-01754-y. Epub 2022 Jul 15. Bone Marrow Transplant. 2022. PMID: 35840747 Free PMC article. Clinical Trial.
Reduced-dose post-transplant cyclophosphamide plus low-dose post-transplant anti-thymocyte globulin as graft-versus-host disease prophylaxis with fludarabine-busulfan-cytarabine conditioning in haploidentical peripheral blood stem cell transplantation: A multicentre, randomized controlled clinical trial.
Zhang W, Gui R, Zu Y, Zhang B, Li Z, Zhang Y, Wang X, Guo S, Zhan X, Fu Y, Song Y, Zhou J. Zhang W, et al. Among authors: zhan x. Br J Haematol. 2023 Jan;200(2):210-221. doi: 10.1111/bjh.18483. Epub 2022 Oct 6. Br J Haematol. 2023. PMID: 36200642 Clinical Trial.
17 results